Fig. 6From: Cost-effectiveness analysis of bortezomib in combination with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (VR-CAP) in patients with previously untreated mantle cell lymphomaCost-effectiveness plane from 1,000 PSA iterations. PSA, probabilistic sensitivity analysis; QALY, quality-adjusted life year; WTP, willingness to payBack to article page